RECK (reversion-inducing cysteine-rich protein with Kazal motifs)基因可以逆轉 v-Ki-ras 所造成的小鼠 NIH3T3 細胞轉型。由於 RECK 蛋白主要功能為調控間質金屬蛋白酶活化，所以具有抑制癌細胞轉移的作用。在 RECK 蛋白結構中段具有三個 serine protease inhibitor-like domains (SPIs) (第 635~654、716~735 和 754~772 個氨基酸) 與 Kazal motif 相似；Kazal motif 是一種具有peptidase inhibitor 的功能區，富含雙硫鍵和一些 α、β 折疊。其中第一段 SPI 與 Kazal motif 一致，稱為 K1，其餘兩段與 Kazal motif 相似但不完全一致，分別稱為 K2，K3。這些 SPI-like domains 可能對於 RECK 抑制 MMP 的蛋白水解能力有調控的作用。
實驗室之前的研究指出 Kazal-like motifs 2~3 對於 RECK 抗癌細胞轉移侵犯扮演重要的角色。所以本研究進一步探討不同 Kazal motif 功能區的短片段對 MMP 活性與癌細胞轉移能力的作用，結果發現 Kazal-like motif 2 可以經由抑制 MMP-9 的分泌與活性而導致癌細胞的侵犯與轉移能力下降。我們推論 Kazal-like motif 2 對於 RECK 抗癌細胞轉移侵犯所扮演的角色是非常重要的。

RECK stands for ‘reversion-inducing cysteine-rich protein with Kazal motifs’. This gene was initially discovered by screening a human fibroblast cDNA library for genes giving rise to reversion-inducing clones when transfected into v-Ki-ras transformed NIH3T3 cells. The key action of RECK is to inhibit matrix metalloproteinases (MMPs), and it has a significant effect on limiting tumor invasion. Located within the middle part of RECK protein are three serine protease inhibitor-like (SPI) domains (635-654,716-735 and 754-772 amino acids, respectively) which are similar to Kazal motif. Kazal motif is a peptidase inhibitor motif containing disulfide bonds with small alpha and beta folds. The first of these SPI is identical to the Kazal motif (named as K1) and the other two SPIs are highly similar to the Kazal motif (named as K2 & K3). Given RECK is a MMP inhibitor, these SPI-like domains are likely to have a significant role in MMP inhibition.
Our previous data indicated that K23 motifs of RECK protein can inhibit MMP-9 secretion and activity and attenuate metastasis of lung cancer cells. To go a step further, we constructed secretory mammalian expression vectors which could produce K1, K2 and K3 to investigate their effect on MMP activity and cell invasion. We found that K2 also exhibited inhibitory activity on MMP activity and cell invasion. Thus, these finding indicate that the K2 domain of RECK function may be developed as a peptide inhibitor of tumor invasion.

中文摘要 2
英文摘要 3
縮寫語 4
前言 5
研究方向 9
實驗材料與方法 10
實驗結果 30
討論 34
圖表及說明 38
參考文獻 51
附圖 54

1.Takahashi C, Sheng ZQ, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 13221-6.
2.Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
3.Furumoto K, Arii S, Mori A, et al. RECK gene expression in hepatocellular carcinoma: Correlation with invasion-related clinicopathological factors and its clinical significance. Hepatology 2001; 33: 189-95.
4.Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002; 2: 161-74.
5.Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 2006; 69: 562-73.
6.Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nature Reviews Cancer 2002; 2: 657-72.
7.Simizu S, Takagi S, Tamura Y, Osada H. RECK-mediated suppression of tumor cell invasion is regulated by glycosylation in human tumor cell lines. Cancer Research 2005; 65: 7455-61.
8.Sasahara RM, Takahashi C, Noda M. Involvement of the Sp1 site in Ras-mediated downregulation of the RECK metastasis suppressor gene. Biochemical and Biophysical Research Communications 1999; 264: 668-75.
9.Sasahara RM, Takahashi C, Sogayar MC, Noda M. Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene. Brazilian Journal of Medical and Biological Research 1999; 32: 891-5.
10.Sasahara RM, Brochado SM, Takahashi C, et al. Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detection and Prevention 2002; 26: 435-43.
11.Liu LT, Chang HC, Chiang LC, Hung WC. Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. Oncogene 2002; 21: 8347-50.
12.Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Research 2003; 63: 3069-72.
13.Laemmli Uk. Cleavage Of Structural Proteins During Assembly Of Head Of Bacteriophage-T4. Nature 1970; 227: 680-685.
14.Takagi S, Simizu S, Osada H. RECK Negatively Regulates Matrix Metalloproteinase-9 Transcription. Cancer Research 2009; 69: 1502-8.
15.Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. American Journal of Respiratory Cell and Molecular Biology 1997; 17: 353-60.
16.Rao JS. Molecular mechanisms of glioma invasiveness: The role of proteases. Nature Reviews Cancer 2003; 3: 489-501.
17.Oh J, Seo DW, Diaz T, et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Research 2004; 64: 9062-9.
18.Valster A, Tran NL, Nakada M, Berens ME, Chan AY, Symons M. Cell migration and invasion assays. Methods 2005; 37: 208-15.
19.Clark JCM, Thomas DM, Choong PFM, Dass CR. RECK - a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer and Metastasis Reviews 2007; 26: 675-83.
20.Chang CK, Hung WC, Chang HC. The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. Journal of Cellular and Molecular Medicine 2008; 12: 2781-9.
21.Laskowski, M., Kato, I. Protein inhibitors of proteinases. Annual Review of Biochemistry 1980; 49: 593-626.
22.McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000; 6: 149-56.